C K Y Ng1, G G Di Costanzo2, N Tosti3, V Paradiso3, M Coto-Llerena4, G Roscigno5, V Perrina3, C Quintavalle3, T Boldanova6, S Wieland4, G Marino-Marsilia7, M Lanzafame3, L Quagliata3, G Condorelli5, M S Matter3, R Tortora2, M H Heim6, L M Terracciano3, S Piscuoglio8. 1. Institute of Pathology, University Hospital Basel, Basel; Hepatology Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland. Electronic address: kiuyancharlotte.ng@usb.ch. 2. Department of Transplantation - Liver Unit, Cardarelli Hospital, Naples. 3. Institute of Pathology, University Hospital Basel, Basel. 4. Hepatology Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland. 5. Department of Molecular Medicine and Medical Biotechnology, "Federico II" University of Naples, Naples, Italy. 6. Hepatology Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland; Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland. 7. Pathology Unit, Cardarelli Hospital, Naples, Italy. 8. Institute of Pathology, University Hospital Basel, Basel. Electronic address: kiuyancharlotte.ng@usb.ch.
Abstract
Background: Hepatocellular carcinomas (HCCs) are not routinely biopsied, resulting in a lack of tumor materials for molecular profiling. Here we sought to determine whether plasma-derived cell-free DNA (cfDNA) captures the genetic alterations of HCC in patients who have not undergone systemic therapy. Patients and methods: Frozen biopsies from the primary tumor and plasma were synchronously collected from 30 prospectively recruited, systemic treatment-naïve HCC patients. Deep sequencing of the DNA from the biopsies, plasma-derived cfDNA and matched germline was carried out using a panel targeting 46 coding and non-coding genes frequently altered in HCCs. Results: In 26/30 patients, at least one somatic mutation was detected in biopsy and/or cfDNA. Somatic mutations in HCC-associated genes were present in the cfDNA of 63% (19/30) of the patients and could be detected 'de novo' without prior knowledge of the mutations present in the biopsy in 27% (8/30) of the patients. Mutational load and the variant allele fraction of the mutations detected in the cfDNA positively correlated with tumor size and Edmondson grade. Crucially, among the seven patients in whom the largest tumor was ≥5 cm or was associated with metastasis, at least one mutation was detected 'de novo' in the cfDNA of 86% (6/7) of the cases. In these patients, cfDNA and tumor DNA captured 87% (80/92) and 95% (87/92) of the mutations, suggesting that cfDNA and tumor DNA captured similar proportions of somatic mutations. Conclusion: In patients with high disease burden, the use of cfDNA for genetic profiling when biopsy is unavailable may be feasible. Our results support further investigations into the clinical utility of cfDNA in a larger cohort of patients.
Background: Hepatocellular carcinomas (HCCs) are not routinely biopsied, resulting in a lack of tumor materials for molecular profiling. Here we sought to determine whether plasma-derived cell-free DNA (cfDNA) captures the genetic alterations of HCC in patients who have not undergone systemic therapy. Patients and methods: Frozen biopsies from the primary tumor and plasma were synchronously collected from 30 prospectively recruited, systemic treatment-naïve HCC patients. Deep sequencing of the DNA from the biopsies, plasma-derived cfDNA and matched germline was carried out using a panel targeting 46 coding and non-coding genes frequently altered in HCCs. Results: In 26/30 patients, at least one somatic mutation was detected in biopsy and/or cfDNA. Somatic mutations in HCC-associated genes were present in the cfDNA of 63% (19/30) of the patients and could be detected 'de novo' without prior knowledge of the mutations present in the biopsy in 27% (8/30) of the patients. Mutational load and the variant allele fraction of the mutations detected in the cfDNA positively correlated with tumor size and Edmondson grade. Crucially, among the seven patients in whom the largest tumor was ≥5 cm or was associated with metastasis, at least one mutation was detected 'de novo' in the cfDNA of 86% (6/7) of the cases. In these patients, cfDNA and tumor DNA captured 87% (80/92) and 95% (87/92) of the mutations, suggesting that cfDNA and tumor DNA captured similar proportions of somatic mutations. Conclusion: In patients with high disease burden, the use of cfDNA for genetic profiling when biopsy is unavailable may be feasible. Our results support further investigations into the clinical utility of cfDNA in a larger cohort of patients.
Authors: Johann von Felden; Amanda J Craig; Teresa Garcia-Lezana; Ismail Labgaa; Philipp K Haber; Delia D'Avola; Amon Asgharpour; Douglas Dieterich; Antoinette Bonaccorso; Miguel Torres-Martin; Daniela Sia; Max W Sung; Parissa Tabrizian; Myron Schwartz; Josep M Llovet; Augusto Villanueva Journal: Oncogene Date: 2020-10-23 Impact factor: 9.867